Editorial: the microbiome, aspirin and colorectal cancer-authors' reply
- PMID: 33205872
- DOI: 10.1111/apt.16115
Editorial: the microbiome, aspirin and colorectal cancer-authors' reply
Comment on
-
Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk.Aliment Pharmacol Ther. 2020 Sep;52(6):976-987. doi: 10.1111/apt.16013. Epub 2020 Aug 8. Aliment Pharmacol Ther. 2020. PMID: 32770859 Free PMC article. Clinical Trial.
-
Editorial: the microbiome, aspirin and colorectal cancer.Aliment Pharmacol Ther. 2020 Dec;52(11-12):1740-1741. doi: 10.1111/apt.16071. Aliment Pharmacol Ther. 2020. PMID: 33205868 No abstract available.
References
REFERENCES
-
- O'Grady J, Quigley EMM. Editorial: the microbiome, aspirin and colorectal cancer. Aliment Pharmacol Ther. 2020;52:1740-1741.
-
- Prizment AE, Staley C, Onyeaghala GC, et al. Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. Aliment Pharmacol Ther. 2020;52:976-987
-
- Zhao R, Coker OO, Wu J, et al. Aspirin reduces colorectal tumor development in mice and gut microbes reduce its bioavailability and chemopreventive effects. Gastroenterology. 2020;159:969-983.e4.
-
- Chao G, Ye F, Shen W, Gong W, Zhang S. Study on the characteristic of intestinal flora in patients with dual antiplatelet therapy. J Drug Target. 2020;28:500-507.
-
- Ahn J, Chen CY, Hayes RB. Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control. 2012;23:399-404.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical